Nomura Securities Upgrades Novo Nordisk (NVO) to Buy Post CRL Sell-Off

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)

Nomura Securities upgraded Novo Nordisk (NYSE: NVO) from Neutral to Buy, which follows Monday's 14 percent sell-off after the company received a CRL from the FDA regarding the NDA for Tresiba and Ryzodeg.

For an analyst ratings summary and ratings history on Novo Nordisk click here. For more ratings news on Novo Nordisk click here.

Shares of Novo Nordisk closed at $165.40 yesterday, with a 52 week range of $129.41-$194.44.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Hewlett-Packard (HPQ) Q2 Performance Wins Praise on Wall Street; Jefferies Raises to Hold
• Maxim Group Upgrades J. C. Penney (JCP) to Buy, Sees 50% Upside
• Macquarie Upgrades IntercontinentalExchange (ICE) to Outperform

Create E-mail Alert Related Categories

Hot Upgrades, Upgrades

Related Entities

Nomura

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?